IPO - Lexaria Bioscience Corp.

Form Type: S-3

Filing Date: 2025-01-22

Corporate Action: Ipo

Type: New

Accession Number: 000164033425000146

Filing Summary: Lexaria Bioscience Corp. filed Form S-3 with the SEC for a registration statement under the Securities Act of 1933 on January 22, 2025. The company seeks to offer and sell up to $50,000,000 in various securities including common stock, warrants, rights, and units at terms that will be determined at the time of the offering. This registration statement allows Lexaria to utilize a continuous offering process under Rule 415, enabling flexibility in the timing and method of sales. As of January 21, 2025, Lexaria's common stock traded at $1.94 on the Nasdaq Capital Market, with a reported market value of approximately $32.5 million, indicating a significant stake held by non-affiliates. The company plans to use the proceeds for research, development, and general corporate purposes. The document outlines potential risks related to investments and includes detailed descriptions of the technology underlying Lexaria's business, namely the DehydraTECH platform, aimed at enhancing the bioavailability of active pharmaceutical ingredients. Lexaria emphasizes the risks associated with investing in their stock and highlights their compliance with reporting requirements under the SEC.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2024-12-03

Corporate Action: Ipo

Type: New

Accession Number: 000164033424001812

Filing Summary: Lexaria Bioscience Corp. has filed a request for the acceleration of its Registration Statement on Form S-3, under File No. 333-283484. The company seeks to have the Registration Statement declared effective on December 5, 2024, at 4:30 PM Eastern time, or as soon thereafter as possible. This request is in accordance with Rule 461 under the Securities Act of 1933. Richard Christopher, the Chief Executive Officer, signed the correspondence.

Document Link: View Document